Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Attending-Level Neurologists at Academic Medical Centers (US)

Articles with lock require a subscription to GLG News | Request a free trial
November 4, 2008
Vimpat approved ONLY for adjunctive therapy of epilepsy
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
Vimpat was developed to have applicability to other disease processes including neuropathic pain. The limited indication approved for Vimpat suggests the data for other potential uses was not very robust (that had been my observation based on the neuropathic pain studies). Although UCB may be developing...
November 3, 2008
UCB's Vimpat (lacosamide) receives FDA approval
Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults | www.pipelinereview.com
Author: GLG Expert Contributor
FDA has approved lacosamide for add-on therapy of partial onset seizures.  It will be marketed by UCB under the brand name Vimpat.
September 11, 2008
Psychotherapy may save money
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists | archpsyc.ama-assn.org
Author: GLG Expert Contributor
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
September 1, 2008
The Devil Is in the Details
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease | www.medicalnewstoday.com
Author: GLG Expert Contributor
This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.
August 6, 2008
Concerns about the Rember Phase 2 data
Analysis of: New Treatment Halts Progress of Alzheimer's Disease | www.abdn.ac.uk
Author: GLG Expert Contributor
While the clinical trial data remain unpublished, those who attended the ICAD conference remain concerned about the possibility that the effects are not as pronounced as the interpretation by the investigators.
April 4, 2008
Another reason to use Lipitor
Analysis of: Lipitor Provided an Unexpectedly Potent Heart Benefit in Patients with Chronic Stable Angina, According to New Study | www.pipelinereview.com
Author: GLG Expert Contributor
Lipitor is the only statin tested to reduce ischemic stroke. The new study also proved its role in reduce angina and MI
April 3, 2008
Another attack to Merck
Analysis of: Merck’s New Cholesterol Pill Has Mixed Results | www.pharmalot.com
Author: GLG Expert Contributor
The potential side effect of liver damage of the new cholesterol agent from Merck will definitely slow or even halt the FDA approval of the medication.
April 1, 2008
Potential new medication in the fight against AD
Analysis of: Lilly Launches Its First Phase III Trial for Treatment of Alzheimer's Disease | www.fiercebiotech.com
Author: GLG Expert Contributor
LY450139 acts through decrease the production of amyloid beta, the protein found in some of AD pathology. This novel mechanism of action carries the hope of halting disease progression.
April 1, 2008
Practise with evidence based medicine
Analysis of: Merck, Schering Plunge as Doctors Discourage Vytorin | www.bloomberg.com
Author: GLG Expert Contributor
Statins are the lipid lowering agents that decrease the incidence of heart attacks and stroke. The other lipide lowering agents, no matter how good the ads. and drug representatives tell you, is unclear
March 28, 2008
It is time to control the price of brand-name medication
Analysis of: Rx Watchdog Report: Trends in Manufacturer Prices of Brand Name Prescription Drugs Used by Medicare Beneficiaries—2002-2007 | www.aarp.org
Author: GLG Expert Contributor
As the population age, more and more patients depend on medicare for their medical care. I do not know how they are going to afford the medication cost with bad economy and elevated drug price

Page : 1 2 3 4 5 6 7 8 Next1 to 10 of 71

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-01T17:45:17.637